Literature DB >> 17940660

Targeting neurological disease with RNAi.

Paul Lingor1, Mathias Bähr.   

Abstract

The neuroscientific community rapidly adopted RNA interference techniques as an experimental tool for the dissection of gene function in vitro and in animal models of neurological disease in vivo. Here, we discuss recent advances in the biotechnical implementation of siRNA/shRNA-mediated gene silencing focusing on issues of design, delivery and putative detrimental effects. We then summarize the current use of RNAi in targeting neurological disease models and give an outlook on the implementation of this technique in clinical therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17940660     DOI: 10.1039/b701169e

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  8 in total

Review 1.  RNAi: a potential new class of therapeutic for human genetic disease.

Authors:  Attila A Seyhan
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

Review 2.  Inhibitory RNA in epilepsy: research tools and therapeutic perspectives.

Authors:  Detlev Boison
Journal:  Epilepsia       Date:  2010-07-15       Impact factor: 5.864

Review 3.  Delivery of small-interfering RNA (siRNA) to the brain.

Authors:  Saroj P Mathupala
Journal:  Expert Opin Ther Pat       Date:  2009-02       Impact factor: 6.674

4.  Cell-penetrating Peptide-mediated therapeutic molecule delivery into the central nervous system.

Authors:  Li-Li Zou; Jie-Lan Ma; Tao Wang; Tang-Bin Yang; Chang-Bai Liu
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

5.  Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.

Authors:  Laura de Yñigo-Mojado; Itziar Martín-Ruíz; James D Sutherland
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

6.  Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages.

Authors:  Ana Paula Perez; Maria Luz Cosaka; Eder Lilia Romero; Maria Jose Morilla
Journal:  Int J Nanomedicine       Date:  2011-11-04

Review 7.  Advances with RNA interference in Alzheimer's disease research.

Authors:  Shun Chen; Xuemei Ge; Yinghui Chen; Nan Lv; Zhenguo Liu; Weien Yuan
Journal:  Drug Des Devel Ther       Date:  2013-02-22       Impact factor: 4.162

8.  Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles.

Authors:  Meenakshi Malhotra; Catherine Tomaro-Duchesneau; Shyamali Saha; Satya Prakash
Journal:  J Pharm (Cairo)       Date:  2013-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.